Number of shares and votes in Ascelia Pharma AB


During April 2021, the number of common shares increased by 5,000,000 as a result of the completed directed new share issue. The number of C-shares also increased in April by 397,641 following a directed share issue and repurchase of these shares (the C-shares are held by Ascelia Pharma). The issue of C-shares is linked to the company's share saving program (LTI 2020), which was resolved by the Annual General Meeting on May 6, 2020.

As of April 30, 2021, the number of shares amounts to 34,576,448, of which 33,668,262 are common shares with one vote per share and 908,186 are C-shares with one tenth of a vote each. The total number of votes in the company amounts to 33,759,080.6. 


Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluri ...

Quarterly Report Q2 2021: Preparing Oncoral for the next level

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2 2021 (April – June 2021), which is now available on the company’s website:

Covid-19 extends recruitment period of SPARKLE study

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the continued global impact of the Covid-19 pandemic could extend the recruitment period of the clinical phase 3 study SPARKLE with up to 6 months. The recruitment is now expected to be completed during H1 2022. Ascelia Pharma has a solid cash position supporting operations well into 2023.